Barbara Krebs-Pohl, Ph.D.

Director

Barbara Krebs Pohl is passionate about science and medicine, an industry veteran with over 27 years of experience in operational and leadership roles, particularly in research and development, business strategy and alliance creation. Dr. Krebs-Pohl is currently a Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine, as well as a Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies across Europe. She recently joined OneChain Immunotherapeutics, a clinical stage private company in Spain aiming at developing novel CAR-T treatments for oncological diseases, as Chair of the Board of Directors.

At MorphoSys AG, where she served most recently as Chief Integration Officer and Chief Business Officer, in Martinsried Germany and Boston Massachusetts, she drove growth, strategic partnerships, and mergers and acquisitions across biotech and large pharma organizations. She led the acquisition and integration of Constellation Pharmaceuticals Inc., strengthening MorphoSys’ oncology leadership, which played a key role in its acquisition by Novartis for $2.9B. She also served on the board of HI-Bio, a clinical stage biotechnology company in San Francisco, California, focusing on severe autoimmune diseases, as a Director, until its acquisition by Biogen for a total of $1.8B. Dr. Krebs-Pohl holds a master of chemistry from University Cologne, a PhD with honors in biochemistry from Medical University Mainz, in cooperation with the Medical Research Center in Cambridge, UK, and trained for General Management and Business Administration at Harvard Business School.